binding affinity News and Research

RSS

Study highlights immune escape mutations in viral N-terminal domain supersite of SARS-CoV-2 spike variants

Researchers characterized SARS-CoV-2 spike (S) isolates extracted from the samples of two individuals infected with the virus in Peru (ΔN25) and Brazil (ΔN135) in January 2021.

6 Apr 2022

Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells

In a recent study published in the journal PLOS Genetics, researchers explored severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ribonucleic acid (RNA) editing in host cells.

4 Apr 2022

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

A team of international scientists has recently isolated and characterized pan-coronavirus neutralizing antibodies from individuals with pre-existing immunity against SARS-CoV-2.

1 Apr 2022

The evolution of the SARS-CoV-2 spike protein

Researchers discuss the evolution and mechanisms of mutations that have occurred in the spike protein of SARS-CoV-2.

31 Mar 2022

Is SARS-CoV-2 a Superantigen?

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), scientists have been conducting extensive studies to understand various aspects of the virus. Researchers have stated that SARS-CoV-2 manifests several biological and clinical consequences of a superantigen

29 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Researchers investigated the impact of mutations in the SARS-CoV-2 variants of interest and variants of concern on the properties of the cluster of differentiation 8 T lymphocytes.

25 Mar 2022

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

25 Mar 2022

Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services

Sino Biological is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.

From Sino Biological Inc. 24 Mar 2022

Study reveals differences in SARS-CoV-2 and SARS-CoV-1 spike protein conformational changes

Researchers determine the differential dynamic behavior of SARS-CoV-1 and SARS-CoV-2 spike proteins.

22 Mar 2022

Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor

Researchers presented a systematic analysis of the affinity and conformational dynamics between the binding of SARS-CoV-2 receptor-binding domain spike protein and the host angiotensin-converting enzyme 2 receptor.

22 Mar 2022

Angiotensin-converting enzyme 2 allosteric binders found to be effective against SARS-CoV-2

Researchers reported a hybrid approach comprising computational models and high throughput screening to discover allosteric ACE2 binders inhibiting viral replication without interrupting ACE2 renal, pulmonary, immune, and cardiovascular functions.

22 Mar 2022

In silico identification of novel curcumin derivatives as potential inhibitors against SARS-CoV-2 enzymes

Researchers identified curcumin derivatives as potential inhibitors of SARS-CoV-2 enzymes.

16 Mar 2022

Acacetin shows potency against SARS-CoV-2 spike protein

Researchers use molecular docking to screen phytocompounds and evaluate their binding affinity with SARS-CoV-2.

15 Mar 2022

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

A new study investigated the broad-spectrum protection provided by hetero-bivalent nanobodies against SARS-CoV-2 variants of concern, such as Omicron.

14 Mar 2022

In silico screening of natural ACE2 inhibitors

Researchers identify potential ACE2 inhibitors through a virtual screening protocol.

14 Mar 2022

Engineered SARS-CoV-2 immunogens elicit broadly neutralizing antibodies

New research describes a novel approach whereby SARS-2 antigens were analyzed for conserved sites that may be targeted by broadly neutralizing antibodies that will confer immunity to other Sarbecoviruses.

10 Mar 2022

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Researchers isolated a large panel of broadly neutralizing antibodies from COVID-19 recovered-vaccinated donors.

10 Mar 2022

Mushroom-derived compounds have potential for use as COVID-19 therapeutic

Researchers conducted virtual screening and validation of molecules derived from mushrooms for their activity against the main protease SARS-CoV-2.

9 Mar 2022

How will mutations change the SARS-CoV-2 spike protein in the future?

A new Cells review discusses the factors that affect the function of the SARS-CoV-2 S protein and provides theoretical limits of this viral protein.

8 Mar 2022

binding affinity News and Research

Study highlights immune escape mutations in viral N-terminal domain supersite of SARS-CoV-2 spike variants

Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

The evolution of the SARS-CoV-2 spike protein

Is SARS-CoV-2 a Superantigen?

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services

Study reveals differences in SARS-CoV-2 and SARS-CoV-1 spike protein conformational changes

Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor

Angiotensin-converting enzyme 2 allosteric binders found to be effective against SARS-CoV-2

In silico identification of novel curcumin derivatives as potential inhibitors against SARS-CoV-2 enzymes

Acacetin shows potency against SARS-CoV-2 spike protein

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

In silico screening of natural ACE2 inhibitors

Engineered SARS-CoV-2 immunogens elicit broadly neutralizing antibodies

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Mushroom-derived compounds have potential for use as COVID-19 therapeutic

How will mutations change the SARS-CoV-2 spike protein in the future?

Binding kinetics in drug discovery eBook eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News